Leading Global Cell Therapy Organizations Support U.S. Department of Justice Appeal of Ruling
(Corrected Copy)
MINNEAPOLIS, Jan 23, 2012 (BUSINESS WIRE) -- A coalition of nine leading international health organizations today issued a statement supporting the U.S. Department of Justice's appeal of the Ninth Circuit Court ruling that allows certain marrow donors to be compensated. Filed Jan. 17, the Justice Department's appeal cites the potential for serious health risks to patients and donors if the ruling stands.
Approximately 5,000 patients each year in the United States receive marrow transplants from unrelated donors to treat leukemia, lymphoma and a number of other diseases. The marrow is a source of stem cells that are critical to restoring the immune system for these patients. Two techniques are used to extract these stem cells. The first draws marrow directly from the donor's hip bone and the second moves the stem cells out of the bone marrow and into the bloodstream using a stimulating hormone, and then collects peripheral blood stem cells (PBSCs) in a procedure similar to the collection of platelets from blood donors.
READ COMPLETE ARTICLE HERE
http://www.businesswire.com/news/home/20120123006041/en/CORRECTING-REPLACING-Leading-Global-Cell-Therapy-Organizations
American Society for Histocompatibility and Immunogenetics
News > CPT Informational Page
CPT Informational Page
ASHI is pleased to provide this CPT Informational page for the convenience and education of the HLA community. Please be aware that sometimes the links may have vendor or third party associations which ASHI neither supports nor promotes. Registration may be required for access to related articles. ASHI is not responsible for emails received from the vendor or third party.
American Society for Histocompatibility and Immunogenetics
News > CPT December 2011 Update
CPT December 2011 Update
American Society for Histocompatibility and Immunogenetics
News > URGENT! ASHI Member Responses Needed to UNOS Proposal
URGENT! ASHI Member Responses Needed to UNOS Proposal
DEADLINE DECEMBER 23!
Dear ASHI Members,
Upon further review of the UNOS proposals out for public comment, it was discovered that the proposed revisions to the UNOS bylaws would have a significant negative impact on the amount of HLA training necessary to direct a histocompatibility laboratory.
While ASHI is going to officially comment on these proposals again as a unified group, it is important to remember that even though we represent Histocompatibility professionals, ASHI's official comment is viewed by OPTN/UNOS as a single comment. Thus, it is important that each of us responds to UNOS individually on these proposals, so that the final revisions of their bylaws truly reflect the specific education and experience necessary to direct a Clinical Histocompatibility Laboratory and provide proper supervision of day-to-day testing.
Our concerns regarding these proposed revisions are <<click here to read more.>>
American Society for Histocompatibility and Immunogenetics
News > Feedback requested by January 24, 2012 on proposed National Patient Safety Goal (NPSG)
Feedback requested by January 24, 2012 on proposed National Patient Safety Goal (NPSG)
There is growing concern related to the overuse of various treatments, procedures, and tests in health care. The Joint Commission defines overuse as the use of a health service in circumstances where the likelihood of benefit is negligible and, therefore, the patient faces only the risk of harm. Seen from this perspective, overuse is a safety and quality problem. Additionally, research has demonstrated that overuse occurs with significant frequency in the United States.
To address this serious safety and quality problem, The Joint Commission is proposing a new National Patient Safety Goal (NPSG) on the topic of overuse and is seeking input from the field. Please review the goal, and then provide comments using one of the methods listed below.
Step 1: Read the Proposed Standards
Note: Prior to submitting your comments, download and review the document(s) below.
*This document requires Adobe Reader.
· Proposed NPSG addressing overuse of treatments, procedures, and tests for Critical Access Hospitals
· Proposed NPSG addressing overuse of treatments, procedures, and tests for Hospitals
Step 2: Provide Your Comments
Tell us what you think. You can submit your comments in one of the following ways:
1. Submit your comments via the online survey, which will take approximately 8 minutes to complete.
2. Submit your comments via the online form.
3. Submit your comments via mail.
The Joint Commission
Standards and Survey Methods
Proposed NPSG on Health Care Overuse
One Renaissance Blvd.
Oakbrook Terrace, IL 60181
Although the usual comment period is 6 weeks, this field review will remain open for 8 weeks because of the holidays. Comments will be gathered for 8 weeks beginning on November 29, 2011 and ending on January 24, 2012.
American Society for Histocompatibility and Immunogenetics
News > International HLA and Immunogenetics Workshop and Joint Conference Abstract Submission
International HLA and Immunogenetics Workshop and Joint Conference Abstract Submission
Abstract Submission is now open for the International HLA and Immunogenetics Workshop and Joint Conference. You're invited to participate in the joint conference of:
- International HLA and Immunogenetics Workshop Conference (IHIW)
- 26th European Immunogenetics and Histocompatibility Conference (EFI)
- 23rd British Society of Histocompatibility and Immunogenetics Conference (BSHI)
Abstract submission is now open
Abstract Submission Deadline: 1st February 2012
http://ihiwefibshi.org/
American Society for Histocompatibility and Immunogenetics
News > 37th Annual Meeting Posters and Abstracts
37th Annual Meeting Posters and Abstracts
Posters and Abstracts submitted to the 37th Annual Meeting may be viewed via the following links:
iPosters (New!)
http://ashi.posterview.com
ASHI Web site
http://www.ashi-hla.org/abstracts/2011/
For download
http://ashi.annualmeeting2011.org/sites/default/files/documents/For%20Web_10.10_1.pdf
American Society for Histocompatibility and Immunogenetics
News > AST Annual Scientific Exchange
AST Annual Scientific Exchange
ASE is for clinicians AND basic scientists. There is an almost equal distribution among basic, clinical, and translational abstracts at ASE, and almost every session includes an Expert Commentary to bridge the gap between basic and clinical. ASE shows you the clinical implications of basic work and the basic questions raised by clinical work. This analysis is critically useful, but often overlooked at other transplant meetings.
ASE is for fellows AND senior faculty. ASE is also dynamic because it is designed just as much for senior faculty and PIs as it is for young investigators and trainees. Both sides benefit from the high level of interaction and discussion that takes place: trainees receive critical feedback that is scarce at other meetings, but which they need desperately. Senior faculty can discuss research in more detail than at other meetings, which opens the door to collaborations and new research directions. This level of interaction is simply not possible at larger meetings.
We hope you will join us in San Antonio December 1-4 for what is sure to be another highly acclaimed Annual Scientific Exchange. Full Program Available Online
American Society for Histocompatibility and Immunogenetics
News > IT’S HERE! The ASHI Annual Meeting App
IT’S HERE! The ASHI Annual Meeting App
Access information about the ASHI 37th Annual Meeting via your smart phone or mobile device. Create a customized schedule, find room locations and view exhibitor information right in the palm of your hand.*
Visit: http://www.ashi-hla.org/images/uploads/ASHI37Flier3.pdf
Visit: http://crwd.cc/ashi37
American Society for Histocompatibility and Immunogenetics
News > In Memoriam - Dr. Charles Bernard Carpenter
In Memoriam - Dr. Charles Bernard Carpenter
Dr. Carpenter was a founding member of the American Society for Histocompatibility and Immunogenetics and served as ASHI president from 1977-78.
http://www.thekidneydoctor.org/2011/10/in-memoriam-dr-charles-bernard.html
American Society for Histocompatibility and Immunogenetics
News > Proposed Revisions to the ASHI Standards
Proposed Revisions to the ASHI Standards
The Quality Assurance and Standards Committee (QAS) has been working on updates to the ASHI Standards. We propose three new standards suggested by the UNOS/OPTN molecular typing of deceased donor's mandate which became effective June 1, 2011. These proposed changes to the Standards have been submitted to the ASHI Board and the Accreditation Review Board (ARB) for review and comment. Now we seek your comments and suggestions.
There is no redline version since the proposed 2011 Standards are new additions to the sections on testing deceased donors for renal/pancreas organ transplantation and testing deceased donors for non-renal organ/tissue transplantation. There are currently no existing standards that are being proposed for changes. Please carefully consider these proposed changes to the current standards and send your comments to Leslie Clark at ASHI Headquarters () no later than September 9, 2011. QAS will respond to all comments received during the public comment period. Implementation of revisions to the standards will be on January 1, 2012 following CMS review.
Please remember that the QAS Committee has certain constraints when responding to your comments. There are two that are noteworthy. First, the proposed standards may not be made more stringent based upon membership comments without a subsequent round of public comment; therefore, such comments will be deferred until the next round of revisions unless the comments are of extraordinary importance. Second, all ASHI Standards must be at least as stringent as the CMS (CLIA) regulations; therefore, proposals that advocate lesser stringency cannot be considered. QAS has worked together to get the proposal to this point, now we need your input. All comments received will be addressed by QAS and our responses will be posted on the ASHI website later this year. We are most appreciative of your participation in the continuous improvement process for the ASHI Standards. Thank you in advance for your time.
Sincerely,
Don Constantino, MS, CHS, QAS Co-Chair
Cynthia Taves, Ph.D., D(ABHI), QAS Co-Chair
American Society for Histocompatibility and Immunogenetics
News > An Opportunity to Advocate for our Renal Transplant Patients
An Opportunity to Advocate for our Renal Transplant Patients
New bipartisan legislation introduced by Senators Durbin and Cochran would assist thousands of renal transplant patients under the age of 65 who are being cut off from Medicare after 36 months by extending coverage of immunosuppressive drugs. To learn more about The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act and what you can do to help get this legislation passed, see http://www.kidney.org/news/newsroom/nr/Durbin_Cochran.cfm
American Society for Histocompatibility and Immunogenetics
News > INFORMATION UPDATE - ASHI’s Call to Action: Public Comment
INFORMATION UPDATE - ASHI’s Call to Action: Public Comment
FDA MAILING ADDRESS - UPDATED (listed below)
Dear ASHI Member:
On June 27th we notified you that the FDA recently published a DRAFT guidance document regarding Research Use Only/Investigational Use Only (RUO/IUO) products. We hope you have already submitted your comments through the FDA web site. If you have not, the DRAFT guidance document can be found here and the page for submission of comments can be accessed here. Deadline for public comment is August 29, 2011.
Since then, the ASHI Board of Directors has determined that the issue of proposed FDA oversight of laboratory developed tests (LDTs) has become so critical that more needs to be done. Thus, we are asking you to write to the FDA as well as your elected officials regarding this topic which is very important to our laboratories, transplant programs and patients. To assist you in this effort, ASHI has drafted the attached template that can be customized and sent to the FDA and/or your government official. The address for the FDA is on the letter, and links are listed below for locating the addresses of your government officials.
We urge you to please take the time to make your opinion heard.
Thank you,
Geof Land, ASHI President
Amy Hahn, ASHI President-Elect
****************************
DOCUMENTS/LINKS
DOWNLOAD TEMPLATE
Customizable Template Letter
(updated 8/2/11)
Send FDA Letter to:
Alberto Gutierrez, Ph.D.
Director of OIVD
Food and Drug Administration
White Oak Office Building 66
10903 New Hampshire Avenue
Silver Spring, MD 20993
LOCATE SENATOR ADDRESS
http://www.senate.gov/general/contact_information/senators_cfm.cfm
LOCATE REPRESENTATIVE ADDRESS
http://www.house.gov/representatives/
(located top right next to map)
VIEW FDA DRAFT GUIDANCE DOCUMENT
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm253307.htm
TO SUBMIT COMMENT
http://www.regulations.gov/#!documentDetail;D=FDA-2011-D-0305-0001
American Society for Histocompatibility and Immunogenetics
News > International Summer School - Deadline Extended
International Summer School - Deadline Extended
This year’s meeting is being organized by ASHI (American Society for Histocompatibility and Immunogenetics) with support from APHIA (Asia-Pacific Histocompatibility and Immunogenetics Association) and EFI (the European Federation for Immunogenetics). The meeting will take place from September 19 -22, 2011 in picturesque Old San Juan, a city rich in history and culture. The meeting organizer is ASHI’s Associate Meeting Manager, Nadège Toth.
The International Summer School is designed to promote the field of Immunogenetics with intensive interaction between participants and tutors. Introductory lectures will be followed by extensive discussions on recent developments. The participants are invited to present their own research. The deadline for submission of documentation to attend has been extended to August 3, 2011. Please see "requirements" listed below.
Location
Sheraton Old San Juan
100 Brumbaugh Street
San Juan, Puerto Rico
Dates
September 19 – 22, 2011
Cost
$200 USD which includes lodging and some meals. Participants must pay for their transportation to and from Old San Juan, Puerto Rico.
Preliminary Faculty
Marcelo Fernández Viña (ASHI)
Geoffrey Land (ASHI)
Rhonda Holdsworth (APHIA)
Narinder Mehra (APHIA)
Ann-Margaret Little (EFI)
Derek Middleton (EFI)
Topics
Immunogenetics of HLA and non-HLA genes
Population genetics
Regulation of gene expression
NK cells and KIR genes
HLA and autoimmunity
Histocompatibility testing
Histocompatibility testing for solid organ and hematopoietic stem cell transplantation
Host-pathogen response
Students
Limited to 35-40 postgraduate fellows, tissue typers or PhD students with some experience in HLA.
Organizers
ASHI (Host), APHIA and EFI
Requirements
If interested in attending the 2011 International Summer School, please send the following documentation for consideration to Melissa Roberts at :
1. Copy of your Curriculum Vitae
2. Letter of motivation
3. An abstract on own research
The deadline for submission of documentation to attend has been extended to August 3, 2011.
For more details, click here.
American Society for Histocompatibility and Immunogenetics
News > CMS Issues Proposed Rule to Retract Physician Signature Requirement - 7/6/11
CMS Issues Proposed Rule to Retract Physician Signature Requirement - 7/6/11
June 30, 2011
© 2011 College of American Pathologists
Statline Special Alert
CMS Issues Proposed Rule to Retract Physician Signature Requirement
June 30—After months of silence on the issue, CMS officials are proposing a rule to retract the physician signature requirement on test requisitions paid under the Clinical Laboratory Fee Schedule (CLFS), acknowledging that the policy could negatively impact patient care and would be difficult to implement. CAP was among the first and strongest opponents of the requirement when CMS first proposed it in the 2011 Physician Fee Schedule (PFS).
If enacted, the signature of a physician or qualified non-physician practitioner (NPP) would have been required on requisitions for tests paid under the CLFS. Initially set to go into effect on Jan. 1, CMS officials indefinitely delayed implementation while they prepared this proposed rule. Because the policy was part of the 2011 PFS, the agency had to issue a notice and request for comment, as it did in today’s Federal Register . After the 60-day comment period closes, a final rule will be released, likely later this year.
CAP’s Steadfast Opposition
Leading opposition to the policy since it was initially proposed in 2010, one of the CAP’s primary concerns has been the potential delay in testing due to lack of signed requisitions and the risk of increased administrative burden to practices and health care providers—including pathologists. The CAP has been working with other stakeholders and lawmakers to oppose the policy and educate the agency, both in written comments and in meetings with CMS officials, on the potential negative impact.
Advocacy efforts on the issue also garnered support from Congress. In early February, Rep. Michael Burgess, MD, (R-TX) brought congressional scrutiny to the issue, sending a letter signed by Rep. Bill Pascrell (D-NJ) and 87 other House members to CMS Administrator Donald M. Berwick, MD, urging his agency to reconsider the regulation. A similar letter was sent by the Senate, signed by Sens. Robert Menendez (D-NJ) and Pat Roberts (R-KS) and co-signed by at least 24 members.
Indeed, the proposed rule acknowledges that the agency received feedback from stakeholders outlining many scenarios where it would be difficult to obtain the physician’s or NPP’s signature on the requisition for laboratory tests under the CLFS. The proposed rule further states that while developing educational outreach material to implement the policy, officials realized how difficult and burdensome the actual implementation of this policy was for physicians and NPPs. In some cases, implementing this requirement could have a negative impact on patient care, prompting agency officials to reexamine the policy.
Rep. Burgess, MD, who serves as the Vice-Chair of the Energy and Commerce Subcommittee on Health, commended CMS for their decision to rescind the rule in a statement to Statline. “The new enforcement was unnecessary and went beyond delaying care,” he stated. “Patients, physicians, hospitals, nursing homes, and laboratories could not afford to have this change implemented, and all supported this effort. I am glad to see that CMS made the right decision in pulling this provision back so that we can put patient care first.”
The comment period for the proposed rule ends on Aug. 29.
American Society for Histocompatibility and Immunogenetics
News > ASHI and The Joint Commission Announce A Cooperative Agreement
ASHI and The Joint Commission Announce A Cooperative Agreement
June 16, 2011
The Joint Commission and the American Society for Histocompatibility and Immunogenetics (ASHI) announce a cooperative agreement to recognize histocompatibility (HLA) accreditation. ASHI will now be accepted as the deemed accreditor for transplant testing services in Joint Commission facilities, effective July 1, 2011.
ASHI is a professional association in the area of HLA, immunogenetics, and transplantation. ASHI, a not-for-profit organization, established its laboratory accreditation program in 1974 for HLA laboratories, and its accreditation program is administered through the ASHI Accreditation Review Board. They are deemed as an accrediting organization through the Clinical Laboratory Improvement Amendments (CLIA) Program. In addition, ASHI accredited labs are recognized by the National Marrow Donor Program (NMDP), United Network for Organ Sharing (UNOS), The American Foundation for Donation and Transplantation (AFDT, formerly SEOPF) and the states of California, Florida, Oregon and Washington. Previously, ASHI was recognized by The Joint Commission under complementary status.
The cooperative status between The Joint Commission and ASHI will reduce the burdens on health care organizations by eliminating the need for duplicate laboratory surveys for organizations conducting HLA testing, and thereby saving them money by accepting the ASHI accreditation as demonstration of compliance with Joint Commission policies and standards. Because ASHI is recognized by United Network for UNOS/ Organ Procurement and Transplantation Network (OPTN) for transplant testing, Joint Commission accredited laboratories will fulfill the requirements for providing testing services for a UNOS transplant program by utilizing ASHI as an accrediting organization.
ASHI will conduct unannounced surveys in Joint Commission accredited facilities. Whenever possible, Joint Commission laboratory surveyors will survey all other specialties simultaneously for organizations that are accredited by both organizations.
“We are delighted to provide this recognition to ASHI. Both our organizations share the mission of an educational and consistent evaluation of diagnostic services. ASHI was the first and still remains the largest accrediting organization for HLA labs providing transplant diagnostic services. Our simultaneous laboratory survey will combine our tracer methodology, which looks at the systematic provision of diagnostic services, with their review of the integrated delivery of transplant care. Both organizations have experience looking at the whole patient care continuum to drive high reliability processes,” says Jennifer Rhamy, M.B.A., M.A., MT (ASCP) SBB, HP, executive director, Laboratory Accreditation Program, The Joint Commission.
“ASHI is very pleased to work with The Joint Commission as detailed in our cooperative agreement. It combines the strengths of both organizations to provide a consistent approach to the accreditation of HLA labs by utilizing uniform standards and survey dynamics. It is a win/win for the laboratories and the organizations as well. The harmonization of a single set of standards for these labs is a tremendous step forward for reducing the burden on laboratories and highlighting the focus of both ASHI and The Joint Commission,” says Geoffrey A. Land, Ph.D., HCLD, president, ASHI.
For more information contact Jennifer Rhamy, at or 630-792-5754.
American Society for Histocompatibility and Immunogenetics
News > ASHI AT FOCIS 2011 - Joint Symposium Eligible for ABHI CECs
ASHI AT FOCIS 2011 - Joint Symposium Eligible for ABHI CECs
The Federation of Clinical Immunology Societies (FOCIS) is the leading collaborative forum for education, research and networking across the broad field of clinical immunology. ASHI has partnered with the American Society for Transplantation (AST) and the Association of Medical Laboratory Immunologists (AMLI) to sponsor two exciting Member Society Symposia. Plus, we have just learned that ABHI has approved the ASHI/AMLI symposium for three (3) CECs - another good reason to attend!
FOCIS 2011 will be held on Thursday, June 23, 2011, at the Marriott Wardman Park Hotel, Washington, D.C.Please join us as we explore the various immunologic issues that bind our community.
For more information on FOCIS 2011:
June 23, 2011 Washington D.C.
http://www.focisnet.org/FOCIS/index.php?option=com_content&task=view&id=120&Itemid=152
ASHI/AST co-sponsored symposium:
June 23, 2011 8:00 am-12:15 pm.
Tolerogenic B Cells and B cell Signatures in Transplant Rejection and Tolerance.
http://www.focisnet.org/FOCIS/images/focis2011/ast-ashi agenda final-3.8.pdf
ASHI/AMLI co-sponsored symposium:
June 23, 2011 12:45 pm-4:15 pm.
Recent Progress in Elucidating the Role of Host Genetics and Immune Responses in Transplantation and Infectious Disease: Implications for the Clinical Immunology/HLA Laboratory.
http://www.focisnet.org/FOCIS/images/focis2011/amli-ashi agenda-4.14.11.pdf
Note: This symposium has been approved for three (3) hours or .45 ABHI CECs.
American Society for Histocompatibility and Immunogenetics
News > Conference Announcement - HLA Epitope Matching in Clinical Transplantation
Conference Announcement - HLA Epitope Matching in Clinical Transplantation
Conference Announcement - HLA Epitope Matching in Clinical Transplantation June 15-16, 2011
This two-day conference addresses the characterization of antibody-defined HLA epitopes and their significance in compatibility testing for transplantation. Analyses of antibody reactivity patterns specific for class I, class II and MICA epitopes are applied to determining mismatch acceptability for sensitized patients and immune monitoring following transplantation. Information about HLA epitope immunogenicity and antigenicity may lead to new donor selection strategies based on permissible mismatching.
Participants are encouraged to present informative cases about epitope matching and there will be demonstrations how to analyze serum reactivity patterns for epitope-specific antibodies. Speakers include Frans Claas (Leiden, The Netherlands), Anat Tambur (Chicago, IL), Stan Stepkowski (Toledo, OH), Adriana Zeevi (Pittsburgh, PA), Ivan Balazs (Stamford, CT), Marilyn Marrari (Pittsburgh, PA) and Rene Duquesnoy (Pittsburgh, PA). An application for continuing education credits is pending. On Wednesday June 15 there will be a social evening in Rosston Eddy Marina including a houseboat ride on the beautiful Allegheny River and a cook-out with live music. If interested in attending, please send an email to Marilyn Marrari and registration information will be forwarded to you.
For more information contact:
Rene J. Duquesnoy, Ph.D. Professor Emeritus of Pathology University of Pittsburgh Medical Center Room 5712 - PUH/South Tower 200 Lothrop Street Pittsburgh, PA 15213 Phone: 1-412-647-6148 Mobile phone: 1-412-860-8083 Fax: 1-412-647-1755 E-mail:
American Society for Histocompatibility and Immunogenetics
News > Law passed requiring CT insurance providers to cover bone marrow tests done at ASHI-accredited labs
Law passed requiring CT insurance providers to cover bone marrow tests done at ASHI-accredited labs
Legislation co-sponsored by State Representative Tony Hwang (R-134) which would require health insurance providers to cover bone marrow testing has now passed the State House of Representatives. Hwang, who shepherded the measure through the Appropriation Committee last month, said the bill will save lives from blood cell cancer and ultimately net long term healthcare cost savings for our state.
Click the link below to read the entire article: http://www.acorn-online.com/joomla15/trumbulltimes/news/localnews/94511-hwang-hails-bone-marrow-bills-passage.html
American Society for Histocompatibility and Immunogenetics
News > Lab Professionals Week - April 26-30, 2011
Lab Professionals Week - April 26-30, 2011
ASHI is a proud sponsor of National Medical Laboratory Professionals Week (NMLPW), an annual celebration of the medical laboratory professionals and pathologists who play a vital role in every aspect of health care. This year, NMLPW will be celebrated from April 24-30, 2011. NMLPW helps laboratory professionals get the recognition they deserve.For ideas on how to celebrate NMLPW in your lab, click here.
To view a list of other sponsors, click here.
Purchase Lab Week promotional items here.
American Society for Histocompatibility and Immunogenetics
News > 2011 Call For Abstracts
2011 Call For Abstracts
The 2011 abstract submission site is now live!
All abstract submission will be peer reviewed and considered for oral or poster presentation. Accepted abstracts will be posted on the ASHI Web site and published in the supplement Human Immunology, which will be available on site at the Annual Meeting.
Submission Site: www.call4abstracts.com/ashi/
Submission Deadline: May 13, 2011 11:59 PM (CDT)
To make your reservations at the Sheraton New Orleans, the official host hotel, click here . The discounted ASHI rate of $239+ tax or club level rooms at $259+tax, all of which include complimentary internet.
American Society for Histocompatibility and Immunogenetics
News > Award Nominations Now Open
Award Nominations Now Open
Each year the American Society for Histocompatibility & Immunogenetics (ASHI) sponsors several awards to recognize scientific accomplishments and contributions to the fields of histocompatibility and immunogenetics, and service to the society. ASHI is currently accepting nominations for the following awards:
The ASHI/SEOPF J. Marilyn Macqueen Award recognizes an outstanding HLA technologist who has worked in the field for less than three years and desires to pursue a career in HLA. The requirement for this award is a short essay written by the nominee of less than four pages describing his/her current work in HLA and why he/she is interested in pursuing a career in the field.
The ASHI Distinguished Service Award was established in 1999 to honor colleagues who have contributed significantly to ASHI’s heritage. The Award recognizes ASHI membership past or present; creativity in moving ASHI in new directions, both scientifically and as an organization; service to ASHI; and educational contribution on behalf of ASHI. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The ASHI Distinguished Scientist Award was established in 2001 to honor a distinguished scientist who is an ASHI member. This individual must have contributed significantly to the field of immunogenetics and/or transplant immunology. The award recognizes ASHI Membership past or present; professional scientific accomplishments: theoretical and technical creativity; special contributions and achievements in their field of expertise; other extraordinary contributions. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The Rose Payne Award recognizes distinguished scientific accomplishment and extraordinary contributions to the immunogenetics community. Specifically, it recognizes contributions to the advancement of histocompatibility and immunogenetics and other extraordinary contributions. ASHI membership is not required. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The Outstanding Technologist Award is presented annually to a technologist who has provided outstanding contributions to the field of histocompatibility and immunogenetics. Nominee must be an ASHI member. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae. Please use the following categories and provide as much detail as possible:
1. Contributions to advancement of technology and science of HLA immunogenetics:
a. Developed/implemented new methods
b. Improved existing methods
c. Authored papers
d. Developed/implemented new programs
e. Service to outside organizations on behalf of HLA/immunogenetics
2. Service to ASHI or ABHI as a committee member, director, officer, or in some other significant way
a. Service on a committee
b. Service as director
c. Service as officer
d. Other extraordinary ASHI service
3. Educational contributions on behalf of ASHI at a regional or national level
a. Presented at regional workshops
b. Coordinated regional/national workshops
c. Taught at educational sessions/national meetings
d. Developed new educational program
e. Taught students, post doctoral fellows, fellows, etc. in own or other lab
Each Awards Committee member will independently award points to each candidate for each of the above categories. Although glowing letters are nice, we urge you to provide appropriate and specific information for each relevant category. Please do not assume that awards committee members are familiar with the accomplishments of your nominee.
4. Certification in histocompatibility
a. Certified Histocompatibility Technologist or Certified Histocompatibility Specialist
5. Other
a. Other pertinent information (explain)
Selection Process
For the Outstanding Technologist Award: If not selected, your nominee will remain under active consideration for a total of three years. unless there are less than four current candidates under consideration. In this case, candidate(s) from the previous year will be included and ranked according to scores received the previous year until a total of four candidates is reached. Updated information for nominations in the second or third year of the cycle is important and strengthens your nominee’s chances for selection. Please do not assume that the OTA subcommittee has access to this updated information unless you provide it.
Nominations for all awards must be received in the ASHI office by MAY 15, 2011.
Send nominations and updates to:
ASHI Executive Office
Attn: Kathy Miranda
15000 Commerce Pkwy, Suite C
Mt. Laurel, NJ 08054
If you have any questions, please contact the ASHI Executive Office at 856-638-0428.
American Society for Histocompatibility and Immunogenetics
News > AFDT Basic Histocompatibility Course
AFDT Basic Histocompatibility Course
Dallas Marriott City CenterDallas, Texas
April 8 - 11, 2011
Purpose: Provide the technician/technologist with a wellrounded background in basic transplant immunology and related laboratory skills and to provide the transplant fellow with basic immunology.
Objective: Meet the needs of the beginning HLA technician/technologist by providing pertinent information about HLA testing, methodologies, and information necessary to meet the ASHI Statement of Competency.
Syllabus: Each student will receive a comprehensive course syllabus containing: -Outline of each lecture; -Notes for each lecture; and -References.
Suggested Requirement for technologists:
1. Minimum three months experience in an HLA Laboratory.
2. B.S. degree in an appropriate biological science or MT(ASCP) or other appropriate registry.
Click below to download the brochure
American Society for Histocompatibility and Immunogenetics
News > Conference Announcement - “HLA Epitope Matching in Clinical Transplantation”
Conference Announcement - “HLA Epitope Matching in Clinical Transplantation”
June 15-16, 2011
This two-day conference addresses the characterization of antibody-defined HLA epitopes and their significance in compatibility testing for transplantation. Analyses of antibody reactivity patterns specific for class I, class II and MICA epitopes are applied to determining mismatch acceptability for sensitized patients and immune monitoring following transplantation. Information about HLA epitope immunogenicity and antigenicity may lead to new donor selection strategies based on permissible mismatching.
Participants are encouraged to present informative cases about epitope matching and there will be demonstrations how to analyze serum reactivity patterns for epitope-specific antibodies. Speakers include Frans Claas (Leiden, The Netherlands), Anat Tambur (Chicago, IL), Stan Stepkowski (Toledo, OH), Adriana Zeevi (Pittsburgh, PA), Ivan Balazs (Stamford, CT), Marilyn Marrari (Pittsburgh, PA) and Rene Duquesnoy (Pittsburgh, PA). An application for continuing education credits is pending. On Wednesday June 15 there will be a social evening in Rosston Eddy Marina including a houseboat ride on the beautiful Allegheny River and a cook-out with live music. If interested in attending, please send an email to Marilyn Marrari and registration information will be forwarded to you.
For more information contact:
Rene J. Duquesnoy, Ph.D. Professor Emeritus of Pathology University of Pittsburgh Medical Center Room 5712 - PUH/South Tower 200 Lothrop Street Pittsburgh, PA 15213 Phone: 1-412-647-6148 Mobile phone: 1-412-860-8083 Fax: 1-412-647-1755 E-mail:
American Society for Histocompatibility and Immunogenetics
News > ASHI’s Response to MEDCAC regarding the use of RBC transfusions vs ESA in renal transplant patients.
ASHI’s Response to MEDCAC regarding the use of RBC transfusions vs ESA in renal transplant patients.
The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) held a January 19, 2011 hearing on “The Impact of Erythropoiesis Stimulating Agents (ESA) on Renal Transplant Survival.” Dr. Susie Leffell presented comments on ASHI’s behalf. To read her testimony, click here.
Following this hearing there was a February 3, 2011 deadline for comments on the technology assessment portion of “The Impact of Pre-Transplant Red Blood Cell (RBC) Transfusions in Renal Allograft Rejection.” The ASHI leadership submitted comments which will be reviewed and posted by May 3, 2011 at http://www.ahrq.gov/clinic/techix.htm. To read these comments now, click here.
American Society for Histocompatibility and Immunogenetics
News > ASHI teams up to fight back against childhood cancer
ASHI teams up to fight back against childhood cancer
Through the Dreyer's and Edy's® brands, ASHI teams up with Nestlé® to fight back against childhood cancer. Click here to learn more about the "Cool Comfort Coupon" campaign.
American Society for Histocompatibility and Immunogenetics
News > Immune Tolerance Network (ITN) Symposium
Immune Tolerance Network (ITN) Symposium
The Immune Tolerance Network (ITN) is an international clinical research consortium founded by the National Institute of Allergy and Infectious Diseases (NIAID), with additional support from the Juvenile Diabetes Research Foundation (JDRF), whose mission is to accelerate the clinical development of immune tolerance therapies. The ITN develops, implements, and conducts trials of novel immune tolerance therapies in type 1 diabetes, autoimmune diseases, solid organ and islet transplantation, and allergy and asthma. ITN trials look beyond the traditional endpoints of safety and efficacy, building into each trial a complementary set of genetic, cellular, and immunological studies that explore the underlying mechanisms of tolerance and disease.
In celebration of the ITN’s 10th anniversary there will be a free one-day symposium, “Ten Years of Tolerance,” on November 1st, 2010, on the NIH campus in Bethesda, MD. The symposium will feature leading tolerance researchers from around the world and will highlight a decade of advancements in clinical tolerance and biomarker discovery. Please contact Laura Straub () if you have any questions about this event.
The full agenda can be found here: www.immunetolerance.org/symposium
For more information about the ITN, please visit www.immunetolerance.org.
American Society for Histocompatibility and Immunogenetics
News > Harmonization of Histocompatibility Typing Terms Statement
Harmonization of Histocompatibility Typing Terms Statement
The purpose of the Harmonization of Histocompatibility Typing Terms Statement is to recommend and to initiate discussion regarding terminology, definitions of resolution levels, format for reporting HLA assignments and match reporting for transplantation. This initiative began in February of 2010. Representative members of the groups listed below have met via conference calls over the past seven months to prepare this document. We now request and welcome your participation in this effort.
Please respond with your comments and suggestions to Leslie Clark () at the ASHI office no later than December 31, 2010. In the subject line indicate that you are responding to the Harmonization of Histocompatibility Typing Terms Statement. Leslie will organize the comments and the Harmonization Group will review all comments in January 2011. The collective Harmonization of Histocompatibility Typing Terms statement will then be made public. It is our hope that each organization will incorporate the terminology and match reporting recommendations into their standards and guidance documents.
Harmonization Group 2010
Marcelo Fernandez-Vina (ASHI)
Harriet Noreen (ASHI, NMDP)
Cyndi Taves (ASHI)
Dawn Wagenknecht (ASHI)
Brad Eisenbrey (CAP)
Gottfried Fischer (EFI)
Carolyn Hurley (NMDP, WMDA)
Helen Heslop (ASBMT)
Eduardo Nunes(AABB)
Kay Poulton (EFI)
Nicoletta Sacchi (W MDA)
Kara Wacker (FACT)
ATTACHMENT FOR REVIEW
Harmonization of Histocompatibility Typing Terms Statement
American Society for Histocompatibility and Immunogenetics
News > Proposed Amended ASHI Bylaws - Response to Public Comment
Proposed Amended ASHI Bylaws - Response to Public Comment
From: ASHI Bylaws Committee
Re: Proposed Amended ASHI Bylaws - Response to Public Comment
Dear Colleagues,
On June 1, 2010, the Bylaws Committee circulated the proposed amended ASHI Bylaws to the membership for comment. The committee has reviewed, discussed and carefully considered all of the comments and recommendations received from the membership. A summary of the comments we received from the membership and the Bylaws Committee’s response to each of those comments can be viewed here.
On behalf of the Bylaws Committee, I would like to thank those who took the time to comment on the proposed amendments to the ASHI Bylaws. A ballot for the approval of the proposed amended ASHI Bylaws will be sent to the membership.
Thank you,
David Kiger
David Kiger, CHS
Bylaws Committee, Chair
American Society for Histocompatibility and Immunogenetics
News > The American Academy of Microbiology Award Nominations
The American Academy of Microbiology Award Nominations
The American Society for Microbiology (ASM) is dedicated to acknowledging the best in microbiology. ASM administers 28 scientific achievement awards. These are annual awards given at the ASM's two large meetings where scientists are honored for their outstanding accomplishments in research, mentoring, education, leadership, and other practices of microbiology. The ASM Awards encompass the many subspecialties of microbiology, including biotechnology, clinical microbiology, environmental microbiology, antimicrobial chemotherapy, immunology, and virology, as well as education and service to the profession. Award nominations are due October 1, 2010.
To learn more about these awards please visit www.asm.org/awards
American Society for Histocompatibility and Immunogenetics
News > Summary of the recent FDA public meeting
Summary of the recent FDA public meeting
A summary of the recent FDA meeting on laboratory developed tests is available on the members only section. To view the summary, visit:
http://www.ashi-hla.org/members/shared-resources/
American Society for Histocompatibility and Immunogenetics
News > Request for Membership Response to Proposed Revisions to the ASHI Standards
Request for Membership Response to Proposed Revisions to the ASHI Standards
To: ASHI Members
From: QAS Committee
Re: Proposed Revisions to the ASHI Standards
Public Comment Period Deadline: Friday, August 27, 2010
Dear ASHI Members:
The Quality Assurance and Standards Committee (QAS) has been working on updates to the ASHI Standards. We propose a new definition and two new standards suggested by partner organizations and working groups. In addition, revisions brought to our attention by other ASHI Committees and ASHI members are among the changes.
These proposed changes to the Standards have been submitted to the ASHI Board and the Accreditation Review Board (ARB) for review and comment. Now we seek your comments and suggestions.
For your convenience, the redline version of the proposed 2010 Standards will allow you to quickly identify changes. In addition, the document entitled "2010 changes to 2009 Standards" provides a side-by-side comparison of the standards which are proposed for change as well as an explanation for each change. Please carefully consider these proposed revisions to the current standards and send your comments to Kathy Miranda at ASHI Headquarters () no later than August 27, 2010.
QAS will respond to all comments received during the public comment period. Implementation of revisions to the standards will be delayed this cycle because ASHI is currently engaged in the renewal process for deemed status by CMS. During the review period, no changes can be made to the ASHI Standards. It is anticipated that the current round of revisions will become effective after April 2011.
Please remember that the QAS Committee has certain constraints when responding to your comments. There are two that are noteworthy. First, the proposed standards may not be made more stringent based upon membership comments without a subsequent round of public comment; therefore, such comments will be deferred until the next round of revisions unless the comments are of extraordinary importance. Second, all ASHI Standards must be at least as stringent as the CMS (CLIA) regulations; therefore, proposals that advocate lesser stringency cannot be considered.
QAS has worked together to get the proposal to this point, now we need your input. All comments received will be addressed by QAS and our responses will be posted on the ASHI website late this year. We are most appreciative of your participation in the continuous improvement process for the ASHI Standards. Thank you in advance for your time.
Sincerely,
Dawn Wagenknecht, MS, CHS, QAS Co-Chair
Cynthia Taves, Ph.D., D(ABHI), QAS Co-Chair
ATTACHMENTS FOR REVIEW
1. Proposed 2010 Standards (redline)
2. 2010 Changes to 2009 Standards (master)
American Society for Histocompatibility and Immunogenetics
News > International Summer School
International Summer School
A limited number of ASHI travel stipends are available to support students/scientists who wish to attend the 2010 International Summer School. Summer school details are available at the meeting website:
www.ashi-hla.org/events/int-ummer-school/
Applicants for travel stipends must supply:
- Completed application, click here.
- Statement of motivation for attending this meeting and a summary of current research
- Letter of support from their supervisor/head of department
- Curriculum Vitae
Travel stipend criteria are listed below:
- Have current ASHI membership
- The applicant must currently be enrolled or have recently completed an advanced degree (Ph.D., MD, or equivalent)
- Research and active technical staff will also be considered
- Have background slides and data (or research plan) for a 20 minute presentation to be given at the Summer School
- Stay for the whole duration of the summer school
American Society for Histocompatibility and Immunogenetics
News > Annual Meeting Registration NOW OPEN!
Annual Meeting Registration NOW OPEN!
Is Hollywood calling your name? Don't miss the ASHI 36th Annual Meeting in Hollywood, Florida September 26th - September 30th, 2010. Securing your spot at the 36th Annual Meeting is just a click away. Register Online Now or download the registration form.
Three Ways to Register
INTERNET
For online registration, click here.
FAX
Fax your completed registration form, including payment information to ASHI Registration Department at: 877-716-6404
MAIL
Mail your completed registration form, including payment information to:
ASHI
Registration Department
15000 Commerce Parkway, Suite C
Mount Laurel, NJ 08054
**All checks must be made payable to ASHI, in U.S. dollars and drawn on a U.S. bank.
Don't forget to visit the ASHI 36th Annual Meeting Web Site for more up to the minute information about this year's annual meeting.
Annual Meeting Web Site
http://www.ashi-hla.org/2010/
American Society for Histocompatibility and Immunogenetics
News > FDA AMR Public Workshop
FDA AMR Public Workshop
FDA AMR Public Workshop is announcing a public workshop regarding scientific issues in clinical development of medical products (i.e., human drugs, therapeutic biological products, and medical devices) for prophylaxis and/or treatment of acute antibody mediated rejection (AMR) in kidney transplant recipients. This public workshop is intended to provide information for and gain perspective from health care providers, academia, and industry on various aspects of development of medical products for prophylaxis and/or treatment of acute AMR in kidney transplant recipients, including clinical trial design and endpoints. The input from this public workshop will help in developing topics for further discussion. For more information, please visit www.fda.gov/Drugs/NewsEvents/ucm206132.htm
American Society for Histocompatibility and Immunogenetics
News > Call for Volunteers
Call for Volunteers
Are you interested in serving on an ASHI committee for the 2010 - 2011 term?
If so, ASHI is looking for dedicated volunteers to serve on its committees. If you are not currently serving on an ASHI committee and would like to do so, please click on the link below to download the volunteer information form.
Volunteer Information Form
Committee Chairs and the Board of Directors will give thoughtful consideration to each request for a committee assignment. Those selected will be notified prior to the Annual Meeting in September 2010. New committee appointments will begin at the conclusion of the Annual Meeting. Click on the link below to download a copy of the list of responsibilities specific to each ASHI committee.
ASHI Committee Responsibilities
Deadline: June 25th
To be considered, please return your completed Volunteer Information Form to the ASHI office either by fax (856-439-0525) or e-mail () no later than June 25th.
American Society for Histocompatibility and Immunogenetics
News > ASHI Bylaws Committee Request Membership Response to Amended Bylaws
ASHI Bylaws Committee Request Membership Response to Amended Bylaws
From: ASHI Bylaws Committee
Dear Colleagues,
The ASHI Bylaws Committee, consisting of Julie Ward, Siva Kanangat, and Lori Osowski, is submitting an amended version of the ASHI Bylaws to the Society members for comment on two (2) revisions:
1. Article II, Section 1. The inclusion of one (1) new membership category, Affiliate Membership.
Rationale: Vendor companies have expressed an interest in joining ASHI to get relevant information that they currently receive indirectly from ASHI members. The Membership Committee submitted a proposal for the introduction of a new "Affiliate Membership" category to the ASHI Board of Directors for consideration and approval in November 2009. The Board approved this proposal. The new "Affiliate Membership" category is recommended for individuals working with ASHI-affiliated companies. They will have the same benefits as the Technologist and Student/Fellow Members.
2. Article II, Section 3. The extension of the Technologist Membership category from a three year term to a five year term.
Rationale: The Technologist Members are eligible to maintain their membership status for three years. After that period of time they are only eligible to be Full Non-Doctoral Members. There was concern in the Membership Committee that the 3-year term may be too short for many Technologists who may not be sure about the benefits of upgrading to the Full Membership. For this reason, the Membership Committee submitted a proposal to the ASHI Board of Directors to extend the Technologist Membership category from three (3) years to five (5) years. This would allow new Technologist Members time to become eligible to take the CHS(ABHI) exam. The Board approved this proposal.
Please click here to view a redline version of the revised Bylaws.
Your comments are important to us. Please take time to review the proposed changes and submit your comments to Kathy Miranda at no later than June 30, 2010. At the conclusion of this 30 day comment period, your comments will be reviewed and considered by the Bylaws Committee. This will allow us time to consider the comments and distribute the revisions for a vote in time for them to be active by the ASHI Annual Meeting. Thank you.
Sincerely,
David Kiger, CHS
Chair of the Bylaws Committee
American Society for Histocompatibility and Immunogenetics
News > Haiti Kidney Transplant Program’s Request for Financial Support
Haiti Kidney Transplant Program’s Request for Financial Support
Haiti hospitals were heavily damaged during the earthquake that struck on January 12, 2010. ASHI has received a request for financial support from The Haiti Transplant Program that we'd like to share with our members and their facilities.
Click here to read the letter from Dr. Jacques Maurice Jeudy.
American Society for Histocompatibility and Immunogenetics
News > 2010 International Summer School - 4/20/10
2010 International Summer School - 4/20/10
This meeting is being organized by EFI (the European Federation for Immunogenetics), ASHI (American Society for Histocompatibility and Immunogenetics) and APHIA (Asia-Pacific Histocompatibility and Immunogenetics Association). The meeting will take place in the beautiful historical town of Messolonghi, Greece from October 3-6, 2010. The local meeting organizer is Catherine Stavropoulos.
This meeting will promote the field of Immunogenetics with an intensive interaction between participants and tutors. Introductory lectures will be followed by extensive discussions on recent developments. The participants are invited to present their own research.
Location: Hotel Theoxenia, Messolonghi, Greece
Dates: October 3-6, 2010
Faculty:
Marcelo Fernandez-Vina (ASHI)
Campbell Witt (APHIA)
Mary Diviney (APHIA)
Sophie Caillat-Zucman (EFI)
Cristina Navarrete (EFI)
Papamatheakis Sifis (EFI)
Frans Claas (EFI)
Topics:
Immunogenetics of HLA and non-HLA genes
Population genetics
Regulation of gene expression.
NK cells and KIR genes
HLA and autoimmunity.
Histocompatibility testing.
Organ- and haematopoietic stem cell transplantation
Host-pathogen response
Students: 25-30 postgraduate fellows, tissue typers or Ph.D. students with some experience in HLA.
Applications for participation are being accepted now. Please send your CV, a letter of motivation and abstract on own research to the local meeting organizer, Prof. Catherine Stavropoulos, at . A small committee consisting of EFI, ASHI and APHIA delegates will select the candidates.
The registration fee is 150 euro including lodging and meals. Participants must pay for their transportation to and from Athens where local transportation will be provided. Deadline for registration is July 1, 2010.
American Society for Histocompatibility and Immunogenetics
News > New Version of HLA Nomenclature Launched April 2010 - 4/16/10
New Version of HLA Nomenclature Launched April 2010 - 4/16/10
The NMDP has updated their website dedicated to the nomenclature change with new language as well as training that was conducted for transplant programs and cord blood banks. Click here for more information: http://www.marrow.org/hla
American Society for Histocompatibility and Immunogenetics
News > Institute for Justice Coalition press release - 3/23/10
Institute for Justice Coalition press release - 3/23/10
For Immediate Release
March 22, 2010
Contact: Catherine Claeys
612-455-1719 / 651-983-4312
Leading Transplant and Transfusion Organizations Join Forces in Effort to Keep Bone Marrow Donation Voluntary
Coalition says overturning federal law to allow donor compensation carries serious risks to patients
MINNEAPOLIS – March 22, 2010 – Voicing concern about the potential impact on patient and donor safety, nine leading international health organizations have formed a coalition to oppose compensating people who provide bone marrow for transplantation.
The organizations — each a leader in the field of transplantation and transfusion therapies — have joined forces in the face of a lawsuit aimed at overturning current U.S. law regarding bone marrow donation. The Institute for Justice is seeking to reverse the National Organ Transplant Act of 1984, as it applies to the prohibition on compensating bone marrow donors.
Bone marrow transplantation can be the best option for a cure for thousands of patients battling leukemia, lymphoma and other critical illnesses.
“Decades of experience and research have shown that a donor system that relies on the human, purely altruistic desire to help others is safer than one that focuses on personal gain,” said Jeffrey W. Chell, M.D., chief executive officer of the National Marrow Donor Program® (NMDP). “There is no sound evidence that compensating donors will save more lives or increase racial diversity of donors. In fact, doing so may expose marrow recipients to greater risks of infectious diseases.”
The coalition includes the NMDP, America’s Blood Centers, AABB (formerly American Association of Blood Banks), the American Society for Blood and Marrow Transplantation, American Society of Histocompatibility and Immunogenetics, the American Society of Transplantation, International Society of Cellular Therapy, The Transplantation Society, and the World Marrow Donor Association.
They oppose changing the current law, citing these reasons:
Protecting Recipient and Donor Safety
A complete and truthful health history is critical to ensure that individuals are eligible to donate and that donated cells are free from infectious diseases. There is a substantial body of experience that people wanting to sell their body parts are more likely to withhold medical details and information that could harm patients.
Maintaining Altruistic Motivations
Studies have shown that compensating donors would deter those who are willing to donate for purely altruistic reasons. The eight million members of the Be The Match
Registry® — in addition to the five million volunteer donors on international registries — are proof that people do not need material incentive to save a life. Current law already allows donors to be reimbursed for out-of-pocket expenses and lost wages. The NMDP and other organizations maintain funds expressly for this purpose.
Avoiding the Creation of Markets in Marrow Donation
Compensation has the potential to create markets for marrow, which could have detrimental effects for both donors and patients. Sellers influenced by possible financial gain could ignore the health risks associated with donation or be coerced by third-party organizations that would profit from a marrow sale. In addition, markets put physicians in the morally dubious position of carrying out medical procedures solely so that sellers may profit.
”The creation of markets is likely to elicit criticism from groups that oppose treating the human body and its parts as property,” said Art Caplan, professor of bioethics at the University of Pennsylvania. “To risk potentially undermining support for marrow donation by allowing donor compensation is irresponsible and short-sighted.”
Ensuring Patients’ Access to Treatment
While the Institute for Justice’s lawsuit alleges compensation might increase patients’ access to bone marrow, the opposite is true.
Changing the U.S. law to allow compensation for marrow donors would set a precedent that could hurt the current voluntary systems for organ and blood donation, potentially undermining some patients’ access to safe organ transplants and blood transfusions. If donors were compensated, the United States would no longer conform to international standards for the use of volunteer donors in cell therapies. Thus, patients in the United States may be unable to have access to the worldwide search process. This would restrict Americans’ chances of finding a match and lives may be lost.
The historical record clearly established that paid blood donors were more likely than voluntary donors to transmit infectious agents, such as HIV and hepatitis viruses. It is a matter of concern that such increased risk could also occur among paid marrow donors.
The NMDP is a global organization that works with leading transplant centers and 70 donor registries in 35 countries. These international partnerships are vital to helping increase patients’ access to potential donors, coalition members say. In fact, about half the transplants facilitated by the NMDP in 2008 involved either an international donor or patient.
“In the best interests of patients and donors, the existing law must be upheld,” said Dr. Chell, who called on U.S. Attorney General Eric Holder to vigorously defend the challenge.
###
American Society for Histocompatibility and Immunogenetics
News > Institute for Justice Coalition - 3/23/10
Institute for Justice Coalition - 3/23/10
ASHI is now a member of the Institute for Justice Coalition. We have received requests from members of the Histocompatibility community, as well as from professional organizations associated with transplantation, to see if ASHI could play a role in the issues of the Coalition. The ASHI Board of Directors felt that their goals are reasonable and would like to support their endeavors.
The coalition was formed to provide information and a public voice in opposition to the notion that marrow and peripheral blood stem cells donors should receive compensation as a result of their donation. The idea of compensation is raised in a lawsuit brought by the Institute for Justice against the United States Attorney General in October 2009, which seeks to overturn a section of the National Organ Transplant Act that forbids compensation to marrow donors.
Our opposition is based on safety, ethical, and practical concerns regarding compensation. These concerns include the possibility that a donor would fail to disclose important personal health or history information that may affect the safety of either the donor or patient. In addition, ethical concerns such as fairness and concern with the potential for extortion are raised. There are 8 million potential donors on the US registry today. These donors joined for altruistic reasons and may feel that if others are willing to donate for compensation, their own selfless act is no longer needed or appreciated. Finally, the compensation of donors in the US may limit the US national registry from participating in the world-wide search for the best donor.
The following organizations have joined this coalition.
American Association of Blood Banks (AABB) - Contact: Karen Shoos-Lipton
8101 Glenbrook Road
Bethesda, MD 20814-2749
Ph: (301) 907-6977
Fax: (301) 907-6895
Established in 1947, AABB is an international, not-for-profit association dedicated to the advancement of science and the practice of transfusion medicine and related biological therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs and services to optimize patient and donor care and safety. AABB membership consists of approximately 1,800 institutions and 8,000 individuals, including physicians, scientists, administrators, medical technologists, nurses, researchers, blood donor recruiters and public relations personnel. Members are located in all 50 states and 80 countries. For more information, please visit www.aabb.org.
America’s Blood Centers - Contact: Jim McPherson
725 15th Street NW, Suite 700
Washington, DC 20005
Ph: (202) 393-5725
Fax:(202) 393-1282
Founded in 1962, America’s Blood Centers is North America’s largest network of community-based, independent blood programs. Recognized by the U.S. Congress for its critical work in patient care and disaster preparedness and response, the federation operates more than 600 blood donor centers providing nearly half of the U.S., and a quarter of the Canadian blood supply. These blood centers serve more than 180 million people and provide blood products and services to more than 3,500 hospitals and healthcare facilities across North America. America’s Blood Centers’ U.S. members are licensed and regulated by the U.S. Food and Drug Administration. Canadian members are regulated by Health Canada.
American Society for Blood and Marrow Transplantation (ASBMT) - Contact: Thomas Joseph
85 W. Algonquin Road, Suite 550
Arlington Heights, IL 60005
Ph: (847) 427-0224
Fax: (847) 427-9656
The American Society for Blood and Marrow Transplantation is a national professional association that promotes advancement of the field of blood and marrow transplantation. ASBMT members are both in clinical practice and in research. Only recently have health professionals in the BMT field had an organization that focuses exclusively on their clinical and research interests. Previously they have had to rely on more general medical and scientific organizations. From its beginning, ASBMT activities have been in eight broad areas, representing the interests of transplant clinicians and investigators and the patients they serve: research, representation, clinical standards, regulation, communications, accreditation, reimbursement, and recruitment and training.
American Society of Histocompatibility and Immunogenetics (ASHI) - Contact: Kathy Miranda
ASHI Executive Office
15000 Commerce Parkway, Suite C
Mt. Laurel, NJ 08054
Ph: (856) 793-0907 Fax:(856) 439-0525
Marcelo Fernandez-Vina (2009-2010 President)
MD Anderson
1515 Holcombe Blvd.
Houston, TX 77030
Ph: (713) 792-2121
The American Society for Histocompatibility and Immunogenetics (ASHI) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics, providing a forum for the exchange of information, and advocating the highest standards of laboratory testing in the interest of optimal patient care. For more information about ASHI, visit www.ashi-hla.org.
American Society of Transplantation (AST) - Contact: Jeremy Chapman, M.D. (Chairman)
153 Clarence Street
Sydney, NSW 2000
Australia
Ph: 61 2 9845 6349
Fax: 61 2 9633 8300
The American Society of Transplantation is an international organization of transplant professionals dedicated to advancing the field of transplantation through the promotion of research, education, advocacy, and organ donation to improve patient care. The Society comprises more than 3,100 transplant physicians, surgeons and allied health professionals. For more information about AST, please visit www.a-s-t.org.
International Society of Cellular Therapy (ISCT) - Contact: Jane Arthurs
Malachite Management Inc.
375 West 5th Avenue, Suite #201
Vancouver, British Columbia
Canada, V5Y 1J6
Ph: (604) 874-4004
Fax: (604) 874-4378
Since 1992, ISCT has been the leading global forum for developing and supporting innovative cellular therapies through communication, education and training. ISCT is a global forum of leading cell therapy experts from 40 countries who drive educational and regulatory activities across all continents. ISCT's Executive Committee and Advisory Board is comprised of world-class scientists, clinicians, technologists, industry and regulatory professionals from across the globe. ISCT is the principal cell therapy society and the only group focused on pre-clinical and translational aspects of developing cell therapy products. As such, ISCT helps the academic, government and biotech/pharma sectors transform research into practice and product. For more information about ISCT, visit http://www.celltherapysociety.org.
World Marrow Donor Association (WMDA) - Contact: Lydia Foeken
WMDA Office
Plesmanlaan 1b, 6th floor
2333 BZ Leiden
The Netherlands
Ph: 31 71 568 5366 (Mon, Tues, Thurs)
Fax: 31 71 521 0457
The World Marrow Donor Association (WMDA) was established in 1989 as a voluntary international network of donor registries and cord blood banks to provide standards and guidelines for donor recruitment, testing, collection, storage, matching and transport of hematopoietic stem cells. WMDA fosters international collaboration to facilitate the exchange of high quality hematopoietic stem cells for clinical transplantation worldwide and to promote the interests of donors. For more information, visit www.worldmarrow.org.
American Society for Histocompatibility and Immunogenetics
News > The HLA Nomenclature Report 2010 is now published - 3/22/10
The HLA Nomenclature Report 2010 is now published - 3/22/10
The HLA Nomenclature Report 2010 is now published. This report contains all of the information on the newly-formatted HLA allele names due to come into operation on April 1, 2010. There are other additions to the HLA Nomenclature included in this report. Click the link below to download the report.
http://www3.interscience.wiley.com/cgi-bin/fulltext/123324121/PDFSTART
American Society for Histocompatibility and Immunogenetics
News > Award Nominations Now Open - 3/17/10
Award Nominations Now Open - 3/17/10
Each year the American Society for Histocompatibility & Immunogenetics (ASHI) sponsors several awards to recognize scientific accomplishments and contributions to the fields of histocompatibility and immunogenetics, and service to the society. ASHI is currently accepting nominations for the following awards:
The ASHI/SEOPF J. Marilyn Macqueen Award recognizes an outstanding HLA technologist who has worked in the field for less than three years and desires to pursue a career in HLA. The requirement for this award is a short essay written by the nominee of less than four pages describing his/her current work in HLA and why he/she is interested in pursuing a career in the field.
The ASHI Distinguished Service Award was established in 1999 to honor colleagues who have contributed significantly to ASHI’s heritage. The Award recognizes ASHI membership past or present; creativity in moving ASHI in new directions, both scientifically and as an organization; service to ASHI; and educational contribution on behalf of ASHI. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The ASHI Distinguished Scientist Award was established in 2001 to honor a distinguished scientist who is an ASHI member. This individual must have contributed significantly to the field of immunogenetics and/or transplant immunology. The award recognizes ASHI Membership past or present; professional scientific accomplishments: theoretical and technical creativity; special contributions and achievements in their field of expertise; other extraordinary contributions. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The Rose Payne Award recognizes distinguished scientific accomplishment and extraordinary contributions to the immunogenetics community. Specifically, it recognizes contributions to the advancement of histocompatibility and immunogenetics and other extraordinary contributions. ASHI membership is not required. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The Outstanding Technologist Award is presented annually to a technologist who has provided outstanding contributions to the field of histocompatibility and immunogenetics. Nominee must be an ASHI member. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae. Please use the following categories and provide as much detail as possible:
1. Contributions to advancement of technology and science of HLA immunogenetics:
a. Developed/implemented new methods
b. Improved existing methods
c. Authored papers
d. Developed/implemented new programs
e. Service to outside organizations on behalf of HLA/immunogenetics
2. Service to ASHI or ABHI as a committee member, director, officer, or in some other significant way
a. Service on a committee
b. Service as director
c. Service as officer
d. Other extraordinary ASHI service
3. Educational contributions on behalf of ASHI at a regional or national level
a. Presented at regional workshops
b. Coordinated regional/national workshops
c. Taught at educational sessions/national meetings
d. Developed new educational program
e. Taught students, post doctoral fellows, fellows, etc. in own or other lab
Each Awards Committee member will independently award points to each candidate for each of the above categories. Although glowing letters are nice, we urge you to provide appropriate and specific information for each relevant category. Please do not assume that awards committee members are familiar with the accomplishments of your nominee.
4. Certification in histocompatibility
a. Certified Histocompatibility Technologist or Certified Histocompatibility Specialist
5. Other
a. Other pertinent information (explain)
Selection Process
For the Outstanding Technologist Award: If not selected, your nominee will remain under active consideration for a total of three years. unless there are less than four current candidates under consideration. In this case, candidate(s) from the previous year will be included and ranked according to scores received the previous year until a total of four candidates is reached. Updated information for nominations in the second or third year of the cycle is important and strengthens your nominee’s chances for selection. Please do not assume that the OTA subcommittee has access to this updated information unless you provide it.
Nominations for all awards must be received in the ASHI office by MAY 15, 2010.
Send nominations and updates to:
ASHI Executive Office
Attn: Kathy Miranda
15000 Commerce Pkwy, Suite C
Mt. Laurel, NJ 08054
If you have any questions, please contact the ASHI Executive Office at 856-638-0428.
American Society for Histocompatibility and Immunogenetics
News > 2009 ASHI Standards available online - 2/12/10
2009 ASHI Standards available online - 2/12/10
The 2009 ASHI Standards are available online at http://www.ashi-hla.org/lab-center/accreditation/forms/standards/.
American Society for Histocompatibility and Immunogenetics
News > HLA Nomenclature Changes effective April 1, 2010
HLA Nomenclature Changes effective April 1, 2010
The main feature of this nomenclature update introduces the use of colons (:) into the allele names to act as delimiters of the separate fields for all HLA loci. The change is seamless for most allele groups or loci; however all alleles of the A*92 and B*95 series will be renamed and will be grouped according to their appropriate loci, such as HLA-A*02 or B*15; some alleles of DPB1 will be renamed and will receive three digit names in the first field.
A detailed description of the HLA Nomenclature update can be viewed by clicking the following links:
http://hla.alleles.org/nomenclature/nomenclature_2009.html
http://hla.alleles.org/announcement.html
The American Society for Histocompatibility and Immunogenetics (ASHI) recognizes that these changes will have a considerable impact on HLA laboratories. These impacts include updating laboratory reports, revising laboratory management software, updating vendor supplied software for typing, and working with unrelated donor registries to incorporate the new nomenclature into search routines. Laboratories will have one year to integrate the nomenclature updates into laboratory analytic systems.
ASHI has been in contact with and working together with the National Marrow Donor Program (NMDP) to gain knowledge about the approaches that they are taking with regard to these changes. The NMDP has drafted a document describing the changes and approaches to accommodate this change. The NMDP announced these initiatives in November 2009. The link to this announcement is:
http://www.marrow.org/HD/HLA/index.html
The announcement states the NMDP will be able to receive results expressed using either current or new nomenclature for one year. After April 1, 2011, all results submitted to NMDP should be expressed according to new nomenclature. A copy of the document drafted by both NMDP and the World Marrow Donor Association (WMDA) is attached below. A link describing the future use of codes and the submission of results electronically to the NMDP is accessible through the following links:
http://bioinformatics.nmdp.org/index.html
http://bioinformatics.nmdp.org/HLA/Ver3_Nomenclature_Allele_Codes/index.html
It should be noted that the NMDP codes for assignment will use a colon character added after the second or third digit followed by the corresponding letter codes. Therefore, laboratories reporting allele codes will need to make the appropriate changes to accommodate the new requirements. The NMDP has developed software tools to convert HLA results to the new nomenclature that will allow transplant centers and laboratories to continue to perform donor and CBU searches with minimal impact during the transition period.
The Accreditation Review Board of ASHI, recognizing the impact on laboratories, will allow a year's time to become compliant with the new nomenclature changes for standard D.5.2.6.4 (Use HLA typing terminology that conforms to the latest report of the W.H.O. Nomenclature Committee for factors of the HLA System. Potential new antigens and/or alleles not yet approved by this committee must have a designation that cannot be confused with W.H.O. terminology.) During this time, laboratories should address these nomenclature changes with their Laboratory Information Systems staff to be sure databases and reports can accommodate the new format. All laboratory clients should receive notification and education on the Nomenclature change.
Additionally, ASHI has contacted vendors of commercial reagents and software with regard to the new changes in HLA nomenclature. Many vendors have indicated that they will have available by April 1, 2010 software versions that accommodate both old and new nomenclature allowing the users to schedule the implementation of the new nomenclature according to the laboratory needs. We recommend that each laboratory contact their vendors concerning the changes that will be made to their products, and how those will impact their laboratory's information systems.
Stay tuned for additional updates as they become available.
American Society for Histocompatibility and Immunogenetics
News > NMDP- Notice of Upcoming Release of Request for Proposal - 12/4/09
NMDP- Notice of Upcoming Release of Request for Proposal - 12/4/09
NATIONAL MARROW DONOR PROGRAM®
Notice of Upcoming Release of Request for Proposal
HLA Typing of Registry Donors: Perform HLA-A, B, and DRB1 Typing on Newly Recruited Volunteer Donors for the Be The Match RegistrySM
The National Marrow Donor Program (NMDP) anticipates releasing a Request for Proposal (RFP C10-0001) during the first quarter of calendar year 2010 for the purpose of soliciting proposals from qualified laboratories to perform high-volume HLA-A, B, and DRB1 typing, at a minimum of intermediate resolution, on volunteer donor samples. The NMDP maintains the Be The Match Registry of over 8 million volunteer donors, with approximately 27,000 new donors HLA-A, B, and DRB1 typed and added to the Registry each month. This high volume HLA typing program currently consists of six laboratories, testing and electronically reporting results on an average total of 6,800 samples per week. HLA results are required to be reported within 14 days from receipt of the samples. Laboratories must be accredited by the American Society of Histocompatibility (ASHI), and be located within the continental United States to be considered for this program. A majority of the donor samples will consist of cotton-tipped buccal swabs. Additional sample types may include 1ml aliquots of frozen anticoagulated peripheral whole blood, 75ul whole blood spotted and dried on S&S ® 903TM filter paper, frozen cord blood, and cotton-tipped swabs containing B-lymphocytic cells.
The NMDP encourages qualified laboratories to examine this upcoming solicitation and consider this opportunity. Laboratories interested in responding to this RFP are encouraged to complete and return the attached form by December 21, 2009. At the time of release, the RFP will be available at http://bioinformatics.nmdp.org/. A qualifying pre-test will be required of those laboratories that are not currently participating in the NMDP donor recruitment typing program, or current participating laboratories submitting a proposal using a substantially different HLA typing technology. The pre-test will be sent after the release of RFP C10-0001, and will consist of thirty-six samples. There will be four sample types: 75μL of whole blood spotted and dried on S&S 903 filter paper, frozen whole blood aliquots, cotton-tipped swabs containing B-lymphocytic cells and cotton-tipped buccal swabs.
Critical laboratory requirements:
1. Must have the ability to perform HLA-A, B, and DRB1 typing on a minimum of 200 samples per week.
2. Must have the ability to complete and electronically report HLA typing results using Histoimmunogenetics Markup Language (HML). Information about HML can be found at http://bioinformatics.nmdp.org/HLA/HLA_Typing/HML/index.html
3. Must maintain accreditation by the American Society for Histocompatibility and Immunogenetics (ASHI) for HSC/BM Transplantation: Unrelated Donor Histocompatibility Testing for Other Clinical Purposes.
A full explanation of all requirements will be described in RFP C10-0001.
General:
This notice is not a Request for Proposal (RFP) and does not commit the NMDP to award a contract now or in the future. This is an information gathering step to assist NMDP in planning the anticipated RFP timeline, contracting and other activities under this program.
American Society for Histocompatibility and Immunogenetics
News > Updated Allele*Frequencies in Worldwide Populations website - 11/12/09
Updated Allele*Frequencies in Worldwide Populations website - 11/12/09
Please visit the Allele*Frequencies in Worldwide Populations http://www.allelefrequencies.net/ and contribute to the growing allele frequencies from around the world.
The website can be found on the ASHI website under Related Links or directly at http://www.ashi-hla.org/links/#mhc.
American Society for Histocompatibility and Immunogenetics
News > The Joint Commission - Laboratory Accreditation Program - 11/2/09
The Joint Commission - Laboratory Accreditation Program - 11/2/09
2010 National Patient Safety Goals
NPSG.01.01.01
Accreditation Program: Laboratory
Chapter: National Patient Safety Goals
Use at least two patient identifiers when providing laboratory services.
Elements of Performance for NPSG.01.01.01
1. Use at least two patient identifiers when administering blood or blood components; when collecting blood samples and other specimens for clinical
testing; and when providing other treatments or procedures. The patient's room number or physical location is not used as an identifier. Note: An
example of "other procedures" includes bone marrow aspirates.
2. Label containers used for blood and other specimens in the presence of the patient.
NPSG.02.03.01
Report critical results of tests and diagnostic procedures on a timely basis.
Elements of Performance for NPSG.02.03.01
1. Collaborate with organization leaders to develop written procedures for managing the critical results of tests and diagnostic procedures that
address the following:
- The definition of critical results of tests and diagnostic procedures
- By whom and to whom critical results of tests and diagnostic procedures are reported
- The acceptable length of time between the availability and reporting of critical results of tests and diagnostic procedures
2. Implement the procedures for managing the critical results of tests and diagnostic procedures.
3. Evaluate the timeliness of reporting the critical results of tests and diagnostic procedures.
NPSG.07.01.01
Comply with either the current Centers for Disease Control and Prevention (CDC) hand hygiene guidelines or the current World Health
Organization (WHO) hand hygiene guidelines.
Elements of Performance for NPSG.07.01.01
1. Implement a program that follows categories lA, IB, and IC of either the current Centers for Disease Control and Prevention (CDC) or the
current World Health Organization (WHO) hand hygiene guidelines.
2. Set goals for improving compliance with hand hygiene guidelines. (See also IC.03.01.01, EP 3)
3. Improve compliance with hand hygiene guidelines based on established goals.
American Society for Histocompatibility and Immunogenetics
News > Attention Independent Histocompatibility Laboratories - 9/3/09
Attention Independent Histocompatibility Laboratories - 9/3/09
Effective 8/3/2009 CMS has awarded the contract for the fiscal intermediary of all Independent Histocompatibility Laboratories and OPA from Riverbend-GBA to Cahaba-GBA. Check out their website www.cahabagba.com for more information and updates on this important change.
American Society for Histocompatibility and Immunogenetics
News > ASHI travel stipends available to the 2009 International Summer School
ASHI travel stipends available to the 2009 International Summer School
A limited number of ASHI travel stipends are available to support students/scientists who wish to attend the 2009 International Summer School. Summer school details are available at the meeting website: http://aseatta2009.net
For more information about the ASHI travel stipend, please click here: http://www.ashi-hla.org/events/int-ummer-school/
American Society for Histocompatibility and Immunogenetics
News > 35th Annual Meeting Registration is Open! - 8/4/09
35th Annual Meeting Registration is Open! - 8/4/09
35th Annual Meeting Registration is Now Open! Please visit the official ASHI Annual Meeting website at http://www.ashi-hla.org/2009/ to register today!
American Society for Histocompatibility and Immunogenetics
News > Public comment period for the NetCord-FACT Cord Blood Standards - 7/23/09
Public comment period for the NetCord-FACT Cord Blood Standards - 7/23/09
NetCord and The Foundation for the Accreditation of Cellular Therapy (FACT) have published the Fourth Edition of the NetCord-FACT International Standards for Cord Blood Collection, Processing, Testing, Banking, Selection, and Release for inspection and public comment. FACT would appreciate feedback from ASHI members. The public comment period lasts until September 28, 2009. The draft and instructions are available on the FACT website at http://factwebsite.org/main.aspx?id=976.
American Society for Histocompatibility and Immunogenetics
News > HLA Nomenclature Update - 6/16/2009
HLA Nomenclature Update - 6/16/2009
Changes to the HLA Nomenclature will be officially introduced in April 2010. Lists of old and new allele names will be made available through the IMGT/HLA Database and will be implemented with the April 2010 release of the database. Click on http://www.ebi.ac.uk/imgt/hla to read the "Nomenclature Announcement".
ASHI will join together with EFI, NMDP, and WMDA (World Marrow Donor Association) to form a task force that will address the changes in nomenclature and provide guidelines to meet the needed changes.
American Society for Histocompatibility and Immunogenetics
News > Submit your abstracts now!
Submit your abstracts now!
Please click the link below to submit your abstract.
American Society for Histocompatibility and Immunogenetics
News > Nominations Now Open for Five ASHI Awards
Nominations Now Open for Five ASHI Awards
Each year the American Society for Histocompatibility & Immunogenetics (ASHI) sponsors several awards to recognize scientific accomplishments and contributions to the fields of histocompatibility and immunogenetics, and service to the society. ASHI is currently accepting nominations for the following awards:
The ASHI/SEOPF J. Marilyn Macqueen Award recognizes an outstanding HLA technologist who has worked in the field for less than three years and desires to pursue a career in HLA. The requirement for this award is a short essay written by the nominee of less than four pages describing his/her current work in HLA and why he/she is interested in pursuing a career in the field.
The Distinguished Service Award was established in 1999 to honor colleagues who have contributed significantly to ASHI’s heritage. The Award recognizes ASHI membership past or present; creativity in moving ASHI in new directions, scientifically and as an organization; service to ASHI; and educational contribution on behalf of ASHI. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The ASHI Distinguished Scientist Award was established in 2001 to honor a distinguished scientist who is an ASHI member. This individual must have contributed significantly to the field of immunogenetics and/or transplant immunology. The award recognizes ASHI Membership past or present; creativity -rhetorical creativity/innovative ideas/technical creativity; contributions to the advancement of histocompatibility and immunogenetics; and other extraordinary contributions. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The Rose Payne Award recognizes distinguished scientific accomplishment and extraordinary contributions to the immunogenetics community. Specifically, it recognizes contributions to the advancement of histocompatibility and immunogenetics and other extraordinary contributions. ASHI membership is not required. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae.
The Outstanding Technologist Award is presented annually to a technologist who has provided outstanding contributions to the field of histocompatibility and immunogenetics. The winner will receive a $1,000 prize. Requirements for nomination consist of a letter of nomination from an ASHI member, two additional supporting letters, and the candidate’s curriculum vitae. Please use the following categories and provide as much detail as possible:
- Contributions to advancement of technology and science of HLA immunogenetics:
- Developed/implemented new methods
- Improved existing methods
- Authored papers
- Developed/implemented new programs
- Service to outside organizations on behalf of HLA/immunogenetics
- Service to ASHI or ABHI as a committee member, director, officer, or in some other significant way
- Service on a committee
- Service as director
- Service as officer
- Other extraordinary ASHI service
- Educational contributions on behalf of ASHI at a regional or national level
- Presented at regional workshops
- Coordinated regional/national workshops
- Taught at educational sessions/national meetings
- Developed new educational program
- Taught students, post doctorates, fellows, etc. in own or other lab
- Certification in histocompatibility
- Certified Histocompatibility Technologist or Certified Histocompatibility Specialist
- Other
- Other pertinent information (explain)
Selection Process
Each Awards Committee member will independently award points to each candidate for each of the above categories. Although glowing letters are nice, we urge you to provide appropriate and specific information for each relevant category. Please do not assume that awards committee members are familiar with the accomplishments of your nominee.
For the Outstanding Technologist Award: If your nominee is not selected, he/she will remain under active consideration for a total of three years. If there are less than four current candidates under consideration, candidate(s) from the previous year will be included and ranked as determined by scores received the previous year. Updated information for nominations in the second or third year of the cycle is important and strengthens your nominee’s chances for selection. Please do not assume that the OTA subcommittee has access to this updated information unless you provide it.
Nominations for all awards must be received in the
ASHI office by June 1, 2009.
All nominations and updates should be sent to:
ASHI Executive Office
15000 Commerce Pkwy, Suite C
Mt. Laurel, NJ 08054
If you have any questions, please contact the ASHI Executive Office at 856-638-0428.
American Society for Histocompatibility and Immunogenetics
News > ASHI to Host Three Educational Workshops in 2009
ASHI to Host Three Educational Workshops in 2009
Immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists active in transplantation medicine are integral in providing transplant patients with organs and stem cells with the best chance of long term success. The ASHI regional education workshops were developed to provide technologists with practical information applicable at the bench, to deal with the challenges of the modern laboratory.
ASHI’s educational programs are critical in bridging the gap between basic science and clinical practice and the histocompatibility laboratory’s evolving role as an integral member of the clinical transplant team. With this knowledge skill, transplant surgeons, physicians, laboratory personnel and organ procurement coordinators all acts as influential players of a team to provide the highest standard of care possible for transplant patients.
Three regional educational workshop programs are developed each year and held in locations across the United States. This year’s workshops will be held March 19–21 in New Orleans, April 23–25 in Los Angeles, and June 11–13 in Baltimore.
“These workshops provide an unmatched opportunity to exchange information on current and emerging discoveries, forge new collaborations and identify future opportunities in the field,” said Deborah Crowe, Ph.D., D(ABHI), president of ASHI.
The regional educational workshops cover relevant topics in histocompatibility and immunogenetics, as well as new technologies, and provide an opportunity to earn continuing education credits. Program highlights this year include:
• HLA typing Methods
• NK/KIR Genotyping
• Antibodies, What’s New and Clinically Significant
• Opportunities in Live Donor/Desensitization
• AutoImmune/Vaccine
• TRALI Update
• Somatic Mutations in HLA Genes
• Engraftment Monitoring/Dual Cords
• Virtual XM/cPRA
American Society for Histocompatibility and Immunogenetics
News > ASHI Meeting Highlights Breakthroughs in Histocompatibility and Immunogenetics Research
ASHI Meeting Highlights Breakthroughs in Histocompatibility and Immunogenetics Research
ASHI wrapped up its 34th Annual Meeting last month in Toronto. Unprecedented attendance and a superior program made this international conference a definite success. The ASHI Annual Meeting is the world’s leading event for immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists, and technologists looking for the latest cutting-edge findings in laboratory, translational, and clinical histocompatibility and immunology.
The ASHI Annual Meeting, held October 27-31, 2008, at the Sheraton Centre in Toronto, drew a crowd of nearly 1,000 attendees. Those attending gained valuable knowledge through the numerous poster presentations, exhibits, and symposia that highlighted the latest science, technology, and products used to conduct research.
More than 265 abstracts were presented at the meeting, complementing an outstanding program of scientific and educational events. Highlights of the meeting included:
• Transfusion Related Acute Lung Injury (TRALI) update
• Interactive workshops
• Immunoregulatory genes and function
• Genome-wide arrays and gene discovery
• Guiding immunotherapy in autoimmunity
• Case studies on solid organ and bone marrow transplantation
As a professional society involved in histocompatibility, immunogenetics, and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care.
The outstanding lineup of speakers and the opportunity for networking has made this the must-go-to event for professionals in the field. “This meeting provides an unmatched opportunity to exchange information on current and emerging discoveries, forge new collaborations and identify future opportunities in the field,” said Deborah Crowe, Ph.D., D(ABHI), president of ASHI. “The ASHI Annual Meeting provides the most comprehensive source of information in the world on immunogenetic research and its application to human care.”
American Society for Histocompatibility and Immunogenetics
News > ASHI Launches Extended Membership Program
ASHI Launches Extended Membership Program
ASHI is pleased to announce the launch of its extended membership program, allowing technologists, students, fellows and international associates membership in the society at a deeply discounted rate. The program is designed to make membership affordable to all histocompatibility and immunogenetics professionals interested in ASHI, regardless of career level.
Full, institutional and emeritus members will maintain the same great membership rates, and will benefit from the increased insight and networking opportunities increased membership will bring. ASHI’s new membership categories include:
- Technologist Members – Non-doctoral and non-supervisory professionals who are new to the field of histocompatibility and immunogenetics and are not prior full members.
- Student/Fellow Members – Students or fellows involved or interested in the field of histocompatibility and immunogenetics.
- International Associates – Individuals not residing and/or working in North America or U.S. Territories involved or interested in the field of histocompatibility and immunogenetics.
If you know someone who qualifies for one of the above categories, invite him/her to become a member. For just $40.00, they will have access to member benefits such as discounted registration fees for ASHI meetings, access to ASHI-U and the ASHI Quarterly. Be sure to tell your colleagues about this incredible offer!
For more information on the American Society for Histocompatibility and Immunogenetics or to become a member, contact Cecilia Blair, Member Services Coordinator, at: 15000 Commerce Parkway, Suite C, Mount Laurel, NJ 08054; (856) 638-0428, , or visit the Web site at http://www.ashi-hla.org.
If you have newsworthy information to add to the ASHI Web site, please contact kmiranda@ahint.com for consideration.